IN THE NEWS
Times of Israel | July 5, 2017
Israeli startup takes aim at Huntington’s disease
Mitoconix Bio nabs $20 million to develop a promising drug for treatment of neurodegenerative disorder
Fierce Biotech | jun 27, 2017
Mitoconix Bio hits $20M series A for neurodegenerative R&D
Preclinical startup Mitoconix Bio has secured a $20 million series A round for its research work on neurological disorders, including its lead candidate for Huntington’s disease.
YAHOO | June 27, 2017
Mitoconix Bio Raises $20 Million
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
GLOBES | 27 Jun, 2017
Neurological therapy co Mitoconix Bio raises $20m
The proceeds will be used to advance Mitoconix Bio’s lead product for the treatment of Huntington’s disease.